Watch for Continued Gains in Shares of Haemonetics Corporation (HAE)

September 12, 2022 10:17:54

Shares of Haemonetics Corporation (NYSE:HAE) traded today at $78.81, eclipsing its 52-week high. Approximately 78,000 shares have changed hands today, as compared to an average 30-day volume of 426,000 shares.

Haemonetics Corporation (NYSE:HAE) is currently priced 37.0% above its average consensus analyst price target of $49.31.

In the past 52 weeks, Haemonetics Corporation share prices are bracketed by a low of $43.50 and a high of $78.81 and is now at $78.26, 80% above that low price.

Haemonetics Corp sells products used to process, handle, and analyze blood. The firm sells products in three categories: Plasma, Blood Center and Hospital. Plasma includes plasma collection devices and disposables, plasma donor management software, and anticoagulant and saline sold to plasma customers. Blood Center includes blood collection and processing devices and disposables for red cells, platelets and whole blood. Hospital, which is comprised of Hemostasis Management, Cell Salvage, Transfusion Management and Vascular Closure products, includes devices and methodologies for measuring coagulation characteristics of blood, surgical blood salvage systems, specialized blood cell processing systems and disposables, blood transfusion management software and vascular closure devices.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: